Stockhub

Aptose Biosciences Inc.: Revision history

View logs for this page

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

14 August 2022

11 August 2022

26 July 2022

  • curprev 18:3318:33, 26 July 2022‎ Chris talk contribs‎ 1,179 bytes +1,179‎ Created page with "Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States. Its clinical programs include APTO-253, which is in Phase 1a/b clinical trial for the treatment of patients with relapsed or refractory blood cancers, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR MDS); and HM43239 that is in Phase 1/2 clinical trial to..." Tag: Visual edit
Retrieved from ‘https://stockhub.co/research/Aptose_Biosciences_Inc.’